Moving the Goalpost Toward Remission: The Case for Combination Immunomodulatory Therapies in Psoriatic Arthritis

Arthritis Rheumatol. 2021 Sep;73(9):1574-1578. doi: 10.1002/art.41765. Epub 2021 Jul 28.

Authors

Jose U Scher¹, Alexis Ogdie², Joseph F Merola³, Christopher Ritchlin⁴

Affiliations

¹ New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, New York.
² University of Pennsylvania Perelman School of Medicine, Philadelphia.
³ Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
⁴ University of Rochester School of Medicine and Dentistry, Rochester, New York.

PMID: 33844461
DOI: 10.1002/art.41765

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antirheumatic Agents / therapeutic use*
Arthritis, Psoriatic / drug therapy*
Drug Therapy, Combination
Humans
Immunomodulation*
Remission Induction*
Treatment Outcome

Substances

Antirheumatic Agents

Grants and funding